{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:20:14Z","timestamp":1791465614967,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.eururo.2017.05.032","type":"journal-article","created":{"date-parts":[[2017,6,3]],"date-time":"2017-06-03T21:45:53Z","timestamp":1496526353000},"page":"952-959","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":348,"title":["Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets"],"prefix":"10.1016","volume":"72","author":[{"given":"Eugene J.","family":"Pietzak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Bagrodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene K.","family":"Cha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N.","family":"Drill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopa","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Isharwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Baez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Zehir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean F.","family":"Bajorin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Dalbagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikmat","family":"Al-Ahmadie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Solit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard H.","family":"Bochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2017.05.032_bib0155","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2017.05.032_bib0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/00365590801948166","article-title":"Histological classification and stage of newly diagnosed bladder cancer in a population-based study from the Northeastern United States","volume":"42","author":"Schned","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0165","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.28147","article-title":"Recurrence of high-risk bladder cancer: a population-based analysis","volume":"119","author":"Chamie","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.05.032_bib0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrc3817","article-title":"Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity","volume":"15","author":"Knowles","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2017.05.032_bib0180","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2017.05.032_bib0185","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eururo.2014.06.050","article-title":"Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder","volume":"67","author":"Kim","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0190","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1038\/ncomms5809","article-title":"Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden","volume":"5","author":"Cazier","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2017.05.032_bib0195","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.celrep.2014.04.038","article-title":"Mutational context and diverse clonal development in early and late bladder cancer","volume":"7","author":"Nordentoft","year":"2014","journal-title":"Cell Rep"},{"key":"10.1016\/j.eururo.2017.05.032_bib0200","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/ng.2799","article-title":"Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy","volume":"45","author":"Balbas-Martinez","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.05.032_bib0205","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/ng.2798","article-title":"Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation","volume":"45","author":"Guo","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2017.05.032_bib0210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.eururo.2017.05.032_bib0215","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1203619","article-title":"Mutational inactivation of STAG2 causes aneuploidy in human cancer","volume":"333","author":"Solomon","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.eururo.2017.05.032_bib0220","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1093\/hmg\/ddt589","article-title":"Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes","volume":"23","author":"Taylor","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.eururo.2017.05.032_bib0225","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2017.05.032_bib0230","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.eururo.2017.05.032_bib0235","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0240","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2017.05.032_bib0245","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1002\/cncr.30219","article-title":"Genomic characterization of response to chemoradiation in urothelial bladder cancer","volume":"122","author":"Desai","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2017.05.032_bib0250","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2017.05.032_bib0255","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1200\/JCO.2015.65.1067","article-title":"Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels","volume":"34","author":"Stadler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0260","doi-asserted-by":"crossref","first-page":"e0119476","DOI":"10.1371\/journal.pone.0119476","article-title":"p53 status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with bacillus Calmette-Guerin: a meta-analysis","volume":"10","author":"Zhou","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2017.05.032_bib0265","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0270","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","article-title":"Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine","volume":"65","author":"Hurst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0275","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2017.05.032_bib0280","doi-asserted-by":"crossref","first-page":"e62483","DOI":"10.1371\/journal.pone.0062483","article-title":"ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors","volume":"8","author":"Balbas-Martinez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2017.05.032_bib0285","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2017.05.032_bib0290","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.4161\/cc.6.19.4754","article-title":"DNA damage response as an anti-cancer barrier: damage threshold and the concept of \u201cconditional haploinsufficiency\u201d","volume":"6","author":"Bartek","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.eururo.2017.05.032_bib0295","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer--a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2017.05.032_bib0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817304669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283817304669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T11:47:52Z","timestamp":1569412072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283817304669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0302283817304669"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2017.05.032","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727690508.793548289","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2017.05.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}